Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc.
- Market cap
- $555.14M
Your view on ACRS
Overview
What the company does, where it operates, and who runs it.
About Aclaris Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Neal S. Walker D.O.,
- Headquarters
- 640 Lee Road, Wayne, PA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Neal S. Walker D.O.,
- Headquarters
- 640 Lee Road, Wayne, PA, US
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research.
The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services.
The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis.
In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Aclaris Therapeutics, Inc.. Starting points for Aclaris Therapeutics, Inc.: EPS -$0.53, beta 0.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Aclaris Therapeutics, Inc.. Trailing twelve-month EPS for Aclaris Therapeutics, Inc. stands at -$0.53. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
4 firms, last 12 months- Strong Buy0
- Buy4
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.16 | −$0.17 | −$0.60 | −$0.69 |
| Lowest estimate | −$0.17 | −$0.19 | −$0.61 | −$0.83 |
| Highest estimate | −$0.15 | −$0.15 | −$0.59 | −$0.61 |
| Number of analysts | 8 | 5 | 8 | 9 |
| A year ago | −$0.16 | −$0.15 | −$0.53 | — |
| Growth vs a year ago | +0.5% | −11.1% | −12.6% | — |
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $1.37M | $1.21M | $6.37M | $5.20M |
| Lowest estimate | $232372.00 | $808333.00 | $5.38M | $873500.00 |
| Highest estimate | $1.98M | $1.62M | $6.91M | $9.71M |
| Number of analysts | 7 | 5 | 7 | 8 |
| A year ago | $1.29M | $2.00M | $7.83M | — |
| Growth vs a year ago | +5.9% | −39.3% | −18.6% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Aclaris Therapeutics, Inc.. Aclaris Therapeutics, Inc. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AGMBAgomAb Therapeutics N.V. American Depositary Shares | Healthcare | Biotechnology | $286.6M | ||
| ALDXAldeyra Therapeutics, Inc. | Healthcare | Biotechnology | $40.5M | ||
| ALMSAlumis Inc. Common Stock | Healthcare | Biotechnology | $568.9M | ||
| ANABAnaptysBio, Inc. | Healthcare | Biotechnology | $1.4B | ||
| IFRXInflaRx N.V. | Healthcare | Biotechnology | $163.6M | ||
| IMUXImmunic, Inc. | Healthcare | Biotechnology | $102.6M | ||
| MLTXMoonLake Immunotherapeutics | Healthcare | Biotechnology | $918.3M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| CLDXCelldex Therapeutics, Inc. | Healthcare | NASDAQ | $2.2B | ||
| CLGNCollPlant Biotechnologies Ltd. | Healthcare | NASDAQ | $8.8M | ||
| CLLSCellectis S.A. | Healthcare | NASDAQ | $103.8M | ||
| CLNNClene Inc. | Healthcare | NASDAQ | $49.2M | ||
| CLRBCellectar Biosciences, Inc. | Healthcare | NASDAQ | $8.9M | ||
| CLVLFClinuvel Pharmaceuticals Limited | Healthcare | OTC | $424.1M | ||
| CLYMClimb Bio, Inc. | Healthcare | NASDAQ | $546.3M | ||
| CLYYFCelyad Oncology S.A. | Healthcare | OTC | $6.7M | ||
| CMB.AXCambium Bio Limited | Healthcare | ASX | — | ||
| CMMBChemomab Therapeutics Ltd. | Healthcare | NASDAQ | $11.1M | ||
| CMNDClearmind Medicine Inc. | Healthcare | NASDAQ | $1.6M | ||
| CMPSCOMPASS Pathways plc | Healthcare | NASDAQ | $1.2B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.01% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.01% | |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $516M in assets | 0.83% | |
| DWASInvesco Dorsey Wright SmallCap Momentum ETF | $376M in assets | 0.55% | |
| SBIOALPS Medical Breakthroughs ETF | $187M in assets | 0.36% | |
| IWCiShares Micro-Cap ETF | $1.2B in assets | 0.11% | |
| VMO.TOVanguard Global Momentum Factor ETF | $477M in assets | 0.11% | |
Largest holders first, then the funds most concentrated in ACRS.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Aclaris Therapeutics, Inc., and how their positions are changing. At a $555.1M market value, institutional positions materially move Aclaris Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Aclaris Therapeutics, Inc. executives and directors. Shares of Aclaris Therapeutics, Inc. have traded between $1.05 and $4.55 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Aclaris Therapeutics, Inc.. Coverage tracks Aclaris Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Aclaris Therapeutics, Inc.